Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to $2.3 million.

  • Ensysce Biosciences' Total Current Liabilities fell 1774.12% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 1774.12%. This contributed to the annual value of $2.2 million for FY2024, which is 3377.68% down from last year.
  • As of Q3 2025, Ensysce Biosciences' Total Current Liabilities stood at $2.3 million, which was down 1774.12% from $2.5 million recorded in Q2 2025.
  • Over the past 5 years, Ensysce Biosciences' Total Current Liabilities peaked at $16.5 million during Q4 2021, and registered a low of $1.3 million during Q2 2024.
  • In the last 5 years, Ensysce Biosciences' Total Current Liabilities had a median value of $3.7 million in 2023 and averaged $5.5 million.
  • Per our database at Business Quant, Ensysce Biosciences' Total Current Liabilities skyrocketed by 145528.35% in 2021 and then crashed by 8295.09% in 2023.
  • Ensysce Biosciences' Total Current Liabilities (Quarter) stood at $16.5 million in 2021, then tumbled by 42.58% to $9.5 million in 2022, then plummeted by 64.78% to $3.3 million in 2023, then tumbled by 33.78% to $2.2 million in 2024, then rose by 4.42% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $2.5 million for Q2 2025, and $1.8 million during Q1 2025.